No Data
No Data
No Data
No Data
No Data
CSE Bulletin: Delist - Tryp Therapeutics Inc. (TRYP)
Toronto, Ontario--(Newsfile Corp. - Le 24 avril/April 2024) - Tryp Therapeutics Inc. (the "Issuer") has announced that further to the press release dated February 8, 2024, the shareholders of Exopharm
newsfileApr 25 03:17
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF) is pleased to announce that the Company's securityholders overwhelmingly approved
AccesswireMar 12 18:00
CSE Bulletin: Reinstatement - Tryp Therapeutics Inc. (TRYP)
Toronto, Ontario--(Newsfile Corp. - le 5 mars/March 2024) - Effective immediately, Tryp Therapeutics Inc. will be reinstated for trading. The Company has rectified the situation that gave rise to the
newsfileMar 6 02:54
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
KELOWNA, BC / ACCESSWIRE / February 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intrave
AccesswireFeb 9 05:00
Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
Psychedelics biotech Tryp Therapeutics (OTCQB:TRYPF) is advancing its psilocybin-based portfolio through several recent milestones. Upcoming Phase 1 For IV Psilocin First, the company received approva
BenzingaJan 9 05:22
Tryp Therapeutics Signs of Definitive Agreement With Exopharm
Seeking AlphaDec 11, 2023 17:53
No Data
No Data